Literature DB >> 16885059

Evaluation of five staging systems in 470 patients with multiple myeloma.

Dimitra Mihou, Irene Katodritou, Kostas Zervas.   

Abstract

We evaluated the prognostic significance of five staging systems in 470 consecutive, previously untreated patients with multiple myeloma diagnosed between 1989 and 2006. The five staging systems were those proposed by Durie and Salmon, Bataille et al., the South West Oncology Group, Weber et al. and the International Staging System. This last proved to be superior to the others.

Entities:  

Mesh:

Year:  2006        PMID: 16885059

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Authors:  Paul Richardson; Constantine Mitsiades; Jacob Laubach; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth Anderson
Journal:  Core Evid       Date:  2010-06-15

2.  Clinical value of new staging systems for multiple myeloma.

Authors:  Jung-Hye Choi; Jae-Hoon Yoon; Seong-Kyu Yang
Journal:  Cancer Res Treat       Date:  2007-12-31       Impact factor: 4.679

3.  The Role of 18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.

Authors:  Shengming Deng; Bin Zhang; Yeye Zhou; Xin Xu; Jihui Li; Shibiao Sang; Wei Zhang
Journal:  Contrast Media Mol Imaging       Date:  2018-07-30       Impact factor: 3.161

Review 4.  Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.

Authors:  Claudio Cerchione; Saad Z Usmani; A Keith Stewart; Martin Kaiser; Leo Rasche; Martin Kortüm; María-Victoria Mateos; Andrew Spencer; Pieter Sonneveld; Kenneth C Anderson
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.